PNC Financial Services Group
CNCR

PNC Financial Services Group’s ETF Series Solutions Trust Range Cancer Therapeutics ETF CNCR Stock Holding History

PNC Financial Services Group’s Portfolio CNCR Stock Details CNCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-400
Closed -$6K – 4774
2022
Q3 		$6K Hold
400
– – ﹤0.01% 3913
2022
Q2 		$6K Buy
+400
New +$6.13K ﹤0.01% 3939

Other funds holding CNCR

BL
BCWM LLC Overland Park, Kansas $353M AUM 20.1% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
CG
Colony Group Boston, Massachusetts $6.66B AUM 18.65% 1-Year Est. Return
Vontobel Holding
Vontobel Holding Zurich, Switzerland $29.1B AUM 22.79% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
PFS
Prospera Financial Services Dallas, Texas $6.89B AUM 37.41% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

PNC Financial Services Group's CNCR Position: Q4 2022 in Review

PNC Financial Services Group sold out of ETF Series Solutions Trust Range Cancer Therapeutics ETF (CNCR) in Q4 2022, closing a stake of 400 shares — an estimated $6K sold.

PNC Financial Services Group first reported a position in CNCR in Q2 2022 and held it in 2 quarters. The position peaked at $6K in Q3 2022. 20 funds tracked by Wall St. Rank hold CNCR as of Q4 2022.

  • PNC Financial Services Group reported no remaining ETF Series Solutions Trust Range Cancer Therapeutics ETF position as of Q4 2022 after selling out during the quarter.
  • PNC Financial Services Group sold 400 ETF Series Solutions Trust Range Cancer Therapeutics ETF shares in Q4 2022, an estimated $6K.
  • PNC Financial Services Group first reported a position in ETF Series Solutions Trust Range Cancer Therapeutics ETF in Q2 2022 and held it in 2 quarters.
  • PNC Financial Services Group's ETF Series Solutions Trust Range Cancer Therapeutics ETF position peaked at $6K in Q3 2022.
  • 20 funds tracked by Wall St. Rank held ETF Series Solutions Trust Range Cancer Therapeutics ETF as of Q4 2022.

Based on PNC Financial Services Group's 13F filing for Q4 2022, filed 10 Feb 2023.